Targeting STAT3 Enzyme for Cancer Treatment

被引:0
|
作者
Arun, Sowmiya [1 ]
Patel, Praveen Kumar [1 ]
Lakshmanan, Kaviarasan [2 ]
Rajangopal, Kalirajan [1 ]
Swaminathan, Gomathi [1 ]
Byran, Gowramma [1 ]
机构
[1] JSS Acad Higher Educ & Res, Dept Pharmaceut Chem, JSS Coll Pharm, Nilgiris 643001, Tamil Nadu, India
[2] Satyabhama Inst Sci & Technol, Sch Pharm, Dept Pharmaceut Chem, Chennai, Tamil Nadu, India
关键词
STAT3; inhibitors; SH-2; domain; proliferation; phosphorylation; hematological malignancies; tyrosine residue; NF-KAPPA-B; SIGNAL TRANSDUCER; TRANSCRIPTION; 3; KEY REGULATOR; EXPRESSION; ACTIVATOR; COMMUNICATION; SUPPRESSOR; APOPTOSIS; REVEALS;
D O I
10.2174/0113895575254012231024062619
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A category of cytoplasmic transcription factors called STATs mediates intracellular signaling, which is frequently generated at receptors on cell surfaces and subsequently sent to the nucleus. STAT3 is a member of a responsible for a variety of human tumor forms, including lymphomas, hematological malignancies, leukemias, multiple myeloma and several solid tumor types. Numerous investigations have demonstrated constitutive STAT3 activation lead to cancer development such as breast, head and neck, lung, colorectal, ovarian, gastric, hepatocellular, and prostate cancers. It's possible to get a hold of the book here. Tumor cells undergo apoptosis when STAT3 activation is suppressed. This review highlights the STAT3 activation and inhibition which can be used for further studies.
引用
收藏
页码:1252 / 1261
页数:10
相关论文
共 50 条
  • [1] Targeting STAT3 in Cancer Immunotherapy
    Zou, Sailan
    Tong, Qiyu
    Liu, Bowen
    Huang, Wei
    Tian, Yan
    Fu, Xianghui
    MOLECULAR CANCER, 2020, 19 (01) : 1 - 19
  • [2] Targeting transcription factor STAT3 for cancer prevention and therapy
    Chai, Edna Zhi Pei
    Shanmugam, Muthu K.
    Arfuso, Frank
    Dharmarajan, Arunasalam
    Wang, Chao
    Kumar, Alan Prem
    Samy, Ramar Perumal
    Lim, Lina H. K.
    Wang, Lingzhi
    Goh, Boon Cher
    Ahn, Kwang Seok
    Hui, Kam Man
    Sethi, Gautam
    PHARMACOLOGY & THERAPEUTICS, 2016, 162 : 86 - 97
  • [3] Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer
    Aziz, Md Abdul
    Sarwar, Md Shahid
    Akter, Tahmina
    Uddin, Md Sahab
    Song Xun
    Yu Zhu
    Islam, Mohammad Safiqul
    Zhang Hongjie
    LIFE SCIENCES, 2021, 268
  • [4] Direct Targeting Options for STAT3 and STAT5 in Cancer
    Orlova, Anna
    Wagner, Christina
    de Araujo, Elvin D.
    Bajusz, David
    Neubauer, Heidi A.
    Herling, Marco
    Gunning, Patrick T.
    Keseru, Gyorgy M.
    Moriggl, Richard
    CANCERS, 2019, 11 (12)
  • [5] Targeting STAT3 in gastric cancer
    Giraud, Andrew S.
    Menheniott, Trevelyan R.
    Judd, Louise M.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (09) : 889 - 901
  • [6] Strategies and Approaches of Targeting STAT3 for Cancer Treatment
    Furtek, Stefanie L.
    Backos, Donald S.
    Matheson, Christopher J.
    Reigan, Philip
    ACS CHEMICAL BIOLOGY, 2016, 11 (02) : 308 - 318
  • [7] Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
    Siveen, Kodappully Sivaraman
    Sikka, Sakshi
    Surana, Rohit
    Dai, Xiaoyun
    Zhang, Jingwen
    Kumar, Alan Prem
    Tan, Benny K. H.
    Sethi, Gautam
    Bishayee, Anupam
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2014, 1845 (02): : 136 - 154
  • [8] Targeting STAT3 in Cancer with Nucleotide Therapeutics
    Lau, Yue-Ting K.
    Ramaiyer, Malini
    Johnson, Daniel E.
    Grandis, Jennifer R.
    CANCERS, 2019, 11 (11)
  • [9] Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain
    Hua, Yaping
    Yuan, Xing
    Shen, Yun-heng
    Wang, Jinxin
    Azeem, Waqas
    Yang, Shuo
    Gade, Alexandra
    Lellahi, Seyed Mohammad
    oyan, Anne Margrete
    Ke, Xisong
    Zhang, Wei-dong
    Kalland, Karl-Henning
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] Targeting STAT3 in cancer: how successful are we?
    Yue, Pedbin
    Turkson, James
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (01) : 45 - 56